secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193125-23-276640
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics reports Q3 loss; FDA requires new avasopasem trial; GRECO trials halted
--------------------------------------------------------------------------------

- FDA issued Complete Response Letter for avasopasem NDA; requires an additional Phase 3 trial for resubmission.
- GRECO-2 (pancreatic cancer) and GRECO-1 (NSCLC) trials halted following futility analyses.
- Workforce reduced by 22 employees (~70%) in August 2023; restructuring charges of $2.3M in Q3.
- Q3 2023 net loss of $15.1M ($0.33 per share) vs. $16.0M ($0.60) in Q3 2022; cash $28.4M.
- Company exploring strategic alternatives including mergers, asset sales; may be required to cease operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/0001193125-23-276640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523276640/d596085d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-276640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer